342: FDA cuts, zombie biotechs, and too much weight loss?
Feb 20, 2025
auto_awesome
Jared Holz, a healthcare market strategist at Mizuho Securities, shares insights into the biotech landscape's challenges and prospects. He discusses the impact of recent FDA cuts on drug manufacturing, raising concerns about staffing shortages. The conversation also dives into the disconnect between pharmaceutical goals for weight loss and patient experiences, plus the rise of 'zombie' biotech companies. Holz emphasizes the importance of accountability in a stagnating market and highlights promising developments in gene therapy despite industry hurdles.
Recent cuts in government health agencies have fueled concerns about the FDA's oversight capabilities and the backlog of drug inspections.
Solid Biosciences' promising gene therapy advancements highlight the competitive landscape of biotech amid scrutiny over excessive weight loss from obesity drugs.
Deep dives
Impact of Government Cuts on Biotech
Recent cuts across government health agencies have raised concerns within the biotech sector, particularly regarding the FDA and its ability to conduct drug manufacturing inspections. The device division faced more severe reductions, primarily affecting probationary staff, which was concerning given the existing backlog of inspections exacerbated by prior staff shortages. The uncertainty around how these layoffs will influence biotech operations remains prevalent, as most drug-focused inspectors appear to be relatively unscathed. As the situation evolves, stakeholders are left questioning the long-term ramifications on drug reviews and interactions with biotech companies.
Advancements in Duchenne Muscular Dystrophy Treatments
Solid Biosciences has reported early, promising results for its gene therapy aimed at treating Duchenne muscular dystrophy, highlighting a significant advance in this therapeutic area. The reported data showed high levels of microdystrophin expression, alongside initial signs of improved cardiac and muscle function among treated patients. This development comes in the context of a highly competitive market, with both Solid and other companies striving to innovate after setbacks with earlier therapies. The evolving landscape reflects a renewed commitment to substantial advancements in gene therapy to address this challenging condition.
Concerns Over Weight Loss Drug Trends
The obesity treatment sector has come under scrutiny as drug companies increasingly push for significant weight loss outcomes, raising ethical and health concerns. Many patients on ongoing trials for medication like Lilly’s retitrutide have reported losing more weight than desired, prompting some to deliberately skip doses or increase calorie intake to avoid excessive weight loss. Experts express concerns about the health risks associated with rapid weight loss, such as pancreatitis and muscle loss, emphasizing the necessity for maintaining metabolic health. The industry faces the challenge of balancing investor demands for weight loss efficacy and the genuine health needs of the patients.
The State of the Biotech Market
A bleak sentiment currently pervades the biotech market, as highlighted by recent discussions among investors and analysts regarding its overall performance and viability. Biotech stocks have generally underperformed over the past years, prompting the recognition of a 'singular stock pickers' market' where successful investments emerge from careful selection rather than broad sector plays. The proliferation of so-called 'zombie companies'—biotechs with significant cash reserves yet lacking viable development paths—raises questions about industry sustainability and investment priorities. Experts suggest that the fundamental problems within the biotech sector stem from oversaturation and a focus on projects without clear market needs, calling for consolidation and strategic recalibration.
Mizuho analyst Jared Holz joins to discuss Adam's column on biotech's dark period. We also talk about Elaine's latest article on the push for greater and greater weight loss from obesity drugs, along with developments at Solid Biosciences and federal job cuts.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode